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Background: ischemic cardiomyopathy is a common and severe compli-
cation of type 2 diabetes. The aim of our work is to study the epidemiological
profile of ischemic cardiomyopathy in diabetic patients.
Patients and methods: we conducted a prospective observational study
collated in the department of cardiology of Mohammed V Military Hospital of
Rabat, between January 2008 and April 2012 concerning 111 patients
admitted for ischemic cardiomyopathy, 61 of whome were diabetic.
Results: The mean age was higher in diabetic patients with a statistically
significant difference between the two groups. A male predominance was
noted in both groups without significant difference. The main cardiovascular
risk factor was hypertension (70%) in diabetic patients (p=0.005) and smoking
(66%) in non-diabetic patients (p = 0.821). The main symptom was dyspnea
in diabetics (66.3%) and chest pain in non-diabetics (68%). Signs found on
electrocardiogram were: repolarization disorders (58% non-diabetics vs 55%
diabetics), Q waves (56% non-diabetics vs 51% diabetics) and left bundle
branch block (34% diabetics vs 26% non-diabetics). The mean left ventricular
ejection fraction was estimated at 28,92% in diabetic patients and at 27,38%
in non-diabetic patients. Coronary angiography has objectified a multi-vessel
disease in 68.8% of diabetic patients and 56% of non-diabetic patients. In
addition to optimal medical treatment, transluminal coronary angioplasty was
performed in 31.1% of diabetic patients vs. 26% of non-diabetic patients and
bypass surgery was performed in 24.5% of diabetics vs. 22% of non-diabetics.
The intra-hospital evolution was marked by 8 deaths in diabetic patients and
2 deaths in non-diabetic patients.
Conclusion: Type 2 diabetes has an effect on morbidity and mortality in
ischemic cardiomyopathy, that emphasize the importance of controlling all
known risk factors in patients with type 2 diabetes and detecting earlier this
disease.
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Backround: Amiodarone is a widely used antiarrhythmic drug in Tunisia
and worldwide. However, its side effects are quite frequent hampering its use
despite its efficacy.
Objective: The purpose of our study was to determin the prevalence of
amiodarone side effects and to analyse its predictors in our population.
Results: From May 1st 2010 to April 30th 2012, 200 consecutive patients
(mean age: 61.9 ± 12.9 years ) were included. Mean duration of amiodarone
therapy was 51.9 ± 48.4 months with a mean dose of 288.1 ± 274.2 g. Atrial
fibrillation ( 81.5%) was the most common indication. Amiodarone side
effects occurred in 144 patients (72%). Refering to multivariate analysis, inde-
pendent predictors were:
– Advanced age (p=0.02), treatment duration (p< 0.001) and cumulative
dose (p< 0.001) for occurrence of all side effects.
– Treatment duration > 6 months (p=0.008) for corneal deposits.
– Age >70 years (p=0.001) and cumulative dose (p<0.00.1 with a loga-
rithmic correlation) for thyroid toxicity.
– Cumulative dose (p<0.001) and thyroid disease history (p=0.047) for
hypothyroidism.
– Age >70 years (p=0.002) and treatment duration (p< 0.001 with a linear
correlation) for cutaneous toxicity.
– Cumulative dose >300 g (p = 0.012) and heart failure (p= 0.05) for bra-
dycardia.
– Cumulative dose >100 g (p= 0.012) for QT prolongation
– Treatment duration (p< 0.001 with a linear correlation) and betablokers
concomittent use (p=0.046) for PR elongation.
– Treatment duration (p<0.001 with an exponential correlation) and con-
comittent VKA use (p=0.018) for hepatic toxicity.
– Treatment duration > 18 months (p=0.009) and concomittent CCB use
(p<0.001) for neurological toxicity.
Conlusion: The results of our study confirmed that amiodarone side
effects are quite frequent in our population, and that in addition to treatment
dose and duration, other predictors for these effects were identified such as
age and some drug associations.
